CRANBURY, N.J., Aug. 8, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at two upcoming conferences in August:
Wedbush 2013 Life Sciences Management Access Conference in New York, NY
Date: Tuesday, August 13, 2013
Time: 10:20 a.m. ET.
Canaccord Genuity 33rd Annual Global Growth Conference in Boston, MA
Date: Thursday, August 15, 2013
Time: 10:30 a.m. ET.
Both presentations will be webcast live through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus' lead programs include the small molecule pharmacological chaperones migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease.
CONTACT: Amicus Therapeutics Sara Pellegrino (609) 662-5044 firstname.lastname@example.orgSource:Amicus Therapeutics, Inc.